{"entity":{"id":"nct06652633","kind":"trial","name":"Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies","aka":[],"tldr":"A phase 3 trial of GLPG CAR T-cell therapy in advanced solid tumours, run by Lakefront Biotherapeutics NV, now recruiting.","summary":"Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies is a phase 3 interventional study registered as NCT06652633 by Lakefront Biotherapeutics NV, with 546 participants planned, started 2024-09-09 and due to reach its primary completion in 2039-07. Interventions recorded: GLPG CAR T-cell therapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06652633","url":"https://clinicaltrials.gov/study/NCT06652633"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06652633","phase":"3","setting":"A Long-term Follow-up Study for Patients Treated With Galapagos CAR T-cell Therapies","sponsor":"Lakefront Biotherapeutics NV","enrolled":546,"outcomes":[]},"route":"/trials/nct06652633/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}